N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 Forearm Immobilization, Metabolic Health, and Muscle Loss
Healthy
Primary: Percent Change in Forearm Glucose Uptake — -73; 127; -95 Percent change in clamp FGU with immob
N/A N=38 Strength Training for Skeletal Muscle Adaptation After Stroke
Stroke
Primary: Change in 1-repetition Maximum (RM) Muscle Strength (Leg Press, Paretic Side) — 126.1; 11.3 lbs
N/A N=20 Preventing the Loss of Muscle and Function in Hospitalized Older Adults
Muscular Atrophy
Primary: The Percent Change in Bilateral Thigh Lean Mass Density (Grams) as Measured by DEXA Scan Will be Compared Between Baseline and After 5-days of Bed Rest — -3.845; -0.249…
N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
N/A N=33 The Effects of Spasticity on Glucose Metabolism in Individuals With Spinal Cord Injury
Spinal Cord Injuries
Primary: Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Resistance — -0.692; 0.23 correlation coefficient — p=0.006
N/A N=37 Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients
Chronic Kidney Disease
Primary: Maximal Oxygen Uptake — 14.5; 15.1 ml/kg/min
N/A N=14 Muscle Capillarization and Sarcopenia
Sarcopenia
Primary: Skeletal Muscle Capillarization — 0.4; 0.2 capillaries per muscle fiber — p=0.27
N/A N=40 Muscle Mass During Space Exploration
Muscle Loss
Primary: Lean Leg Mass — -1.2; -0.9 g
N/A N=9 Translational Control of Anabolic Resistance in Aging Muscle
Physical Inactivity
Primary: Lean Mass — 403 grams
Phase 2 N=67 Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults
Muscle Atrophy · Quality of Life
Primary: MRI Quadriceps Involved Leg — 43.87; 38.31 AU — p=.03
N/A N=33 Novel Intervention to Influence Muscle Plasticity in Veterans
Spinal Cord Injuries
Primary: HF Muscle Force — 23.9; 30.9 Newtons (N)
N/A N=30 Nutritional Biomarkers of Sarcopenia
Sarcopenia
Primary: Resting and Maximum Plasma Leucine Concentration — 659; 755; 721; 95 micromoles per liter
N/A N=44 Mechanisms Underlying Local and Systemic Effects of Massage
Muscle Atrophy
Primary: Percent Change in Myofiber Cross Sectional Area (CSA). — -15.1; -13.4 percent change from baseline
N/A N=22 Regulation of Muscle Protein Phenotype in Humans With Obesity
Obesity
Primary: Whole-Muscle Protein Synthesis — 0.004; 0.015 %/hr
N/A N=68 Blood Flow, Muscle Regeneration and Sarcopenia
Sarcopenia
Primary: Muscle Satellite Cells — 3.2; 3.2; 4.0; 3.8 Number of Pax7+ cells/muscle fiber
N/A N=40 E-Stim and Achilles Tendon Repair Study
Achilles Tendon Rupture
Primary: Reduce Calf Muscle Atrophy — 859.8; 874.9; 1450.4; 1634.9 mm^2
Phase 2 N=201 A Study in Older Participants Who Have Fallen and Have Muscle Weakness
Muscle Weakness
Primary: Change From Baseline to 24 Week Endpoint in Appendicular Lean Body Mass (aLBM) — 0.303; -0.123 kilograms (kg) — p=<0.001
Phase 2 N=20 Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears
Rupture of Anterior Cruciate Ligament
Primary: Normative Isokinetic Knee Extension Strength, Measured in Newton Meters (Nm) at 26 Weeks Post-op — 0.881; 0.681 Nm — p=0.0498
N/A N=40 Assessment of Body Composition and Physical Function
Body Composition · Physical Function
Primary: Fat Mass — 44.71 Kg
N/A N=16 Effect of an EAA/Whey Composition on Protein Metabolism
Sarcopenia
Primary: Protein Anabolism — 3.56; 11.8; 3.02 grams — p=<0.05
N/A N=22 Diagnosing Intensive Care Unit (ICU) Acquired Weakness
ICU Acquired Weakness
Primary: Peak Acceleration Measured in Extensor Carpi Radialis Longus — 0.476; 1.639; 0.541; 1.608 units of Gravity
N/A N=95 Identifying Therapeutic Targets of Accelerated Sarcopenia
Sarcopenia · Diabetes Mellitus · Aging
Primary: Leg Lean Mass — 0.35; -0.55; -0.80; -0.44 kg — p=<0.01
Phase 2 N=251 Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
Muscle Wasting (Atrophy) After Hip Fracture Surgery
Primary: Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 — 1.066; 1.052; 1.059; 1.009 kg — p=<.0001
Phase 2 N=120 Metformin and Muscle in Insulin-resistant Older Veterans
Prediabetes
Primary: Change in Total Lean Mass From Baseline — 322.8; 697.6; 392.4; 548.0 grams lean mass — p=0.45
N/A N=17 Palliative Strategies in Spinal Cord Injury (SCI)
Spinal Cord Injury
Primary: Muscle Mass Via Dual-Energy X-ray Absortiometry (DEXA)Scan Data — 6104.45; 6355.3 grams — p=.318
Phase 3 N=28 Carnitine Supplementation and Skeletal Muscle Function
Sarcopenia
Primary: Blood Inflammatory Marker — 2.6; 1.8; 2.9; 1.7 mg·L^-1
Phase 2 N=25 Prevention of Skeletal Muscle Adaptations to Traumatic Knee Injury and Surgery
Anterior Cruciate Ligament Reconstruction
Primary: Cross-sectional Area of Skeletal Muscle Fibers (All Fibers) — 2827; 3318; 2206; 2376 micrometer squared — p=<0.05
Phase 2 N=170 A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)
Sarcopenia
Primary: Change From Baseline in Participant Lean Body Mass — 1.26; 0.29 kg
N/A N=99 Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise
Stroke · Inflammation
Primary: Cardiovascular Fitness (VO2 Peak) — 15.9; 16.6; 21.3; 17.5 ml/kg/min — p=0.001